Nuvation Bio (NUVB) Stock Forecast & Price Target

Nuvation Bio is poised for success with its diverse pipeline of oncology product candidates, including taletrectinib, its lead molecule with potential approval in the treatment of ROS1+ NSCLC. The recent licensing agreement with Eisai will significantly expand the global reach of taletrectinib and bring in substantial upfront and milestone payments, further strengthening Nuvation Bio's financials. Risks to achieving our price target and OUTPERFORM rating include potential delays in trial enrollment and/or IND filings, competition from other companies, and regulatory or commercial challenges.

Nuvation Bio is expected to report $21MM in revenue for 1Q26, which will likely be the biggest sales increase within the class with users expected to grow from 12% in front-line settings to 20% within the next six months, highlighting an advantageous market position. The rising number of physician adopters further reinforces this theory, and with increased sales outreach opportunities, we anticipate a decline in discontinuation rates, resulting in the strengthening of revenue growth as patients endure extended treatment durations, justified by the median DOR of ~50 months. Additionally, amending the asset contract with Daiichi Sankyo, accompanied by the exceptional novel candidate activity and rates in Japanese patients, will further support the growth in value for NUVB, providing increased revenue stack momentum in the ~$5.8B valuation. Continued detrimental COVID-19 implications and the risks of dilution could prevent the stock from meeting the $17 price target.